Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and Pomalidomide in R/R AL Amyloidosis
NCT04895917Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab and pomalidomide in amyloid light chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Rate of good quality (CR+VGPR) hematologic response at 6 months. Started Jun 2021; status: terminated.
02
Drugs
daratumumabpomalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04895917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895917.